Journal of the American Veterinary Medical Association · 2010 · 48 citations · 14 references
Veterinary MedicineVeterinary Clinical SciencesVeterinary Internal MedicineCanine Internal MedicineFeline Internal MedicineSmall Animal Internal MedicineMetabolic DisordersMyasthenia GravisClinical RemissionClinical Signs DetectionKaplan-meier Confidence IntervalsMycophenolate-based RegimensPyridostigmine TherapyPyridostigmine TreatmentRetrospective Case AscertainmentSerum Thyroid-stimulating Hormone Measurement
OBJECTIVE-To compare clinical outcome in dogs with serologically diagnosed acquired myasthenia gravis (MG) treated with pyridostigmine bromide (PYR) with that of dogs treated with mycophenolate mofetil (MMF) and PYR (MMF + PYR). DESIGN-Retrospective case series. ANIMALS-27 dogs. PROCEDURES-Medical records from August 1999 through February 2008 were reviewed to identify dogs with serologically diagnosed acquired MG treated with PYR or MMF + PYR. Data collected for each dog included signalment, whether the dog had megaesophagus or pneumonia (or both), thyroid hormone concentration, remission, time to remission, and survival time. Rates for detection of clinical signs and survival time were compared. Survival time was estimated via the Kaplan-Meier method. Influence of drug treatment protocol on likelihood of remission, time to remission, and survival time was examined. Effects of MMF treatment, megaesophagus, pneumonia, and low serum thyroid hormone concentration on time to remission and survival time were also analyzed. RESULTS-12 dogs were treated with PYR, and 15 were treated with MMF + PYR. Mortality rates were 33% (PYR) and 40% (MMF + PYR). There was pharmacological remission in 5 and 6 dogs in the PYR and MMF + PYR groups, respectively. No significant differences were detected between treatment groups for remission rate, time to remission, or survival time. Megaesophagus, pneumonia, and low serum thyroid hormone concentration had no significant effect on time to remission or survival time for either treatment group. CONCLUSIONS AND CLINICAL RELEVANCE-The results did not support routine use of MMF for the treatment of dogs with acquired MG.
14
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Donald B. Sanders, I. K. Hart, Renato Mantegazza et al. · Neurology · 2008 · 313 citations
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
Vinay Chaudhry, David R. Cornblath, John W. Griffin et al. · Neurology · 2001 · 262 citations · Full text
Mycophenolate mofetil for myasthenia gravis: An open-label pilot study
Emma Ciafaloni, Janice M. Massey, B. Tucker–Lipscomb et al. · Neurology · 2001 · 185 citations · Full text
Mycophenolate mofetil for myasthenia gravis
Matthew N. Meriggioli, Emma Ciafaloni, Kefah Al‐Hayk et al. · Neurology · 2003 · 146 citations